They Already Ruined Cannabis. Now Psychedelics Are Next.
The clinical evidence is real. The valuations are not. Compass Pathways: $560 million market cap, zero revenue. MindMed: up to $2 billion, zero revenue. Even Ozempic lost half its value with $49 billion in real sales. When this bubble pops, the casualties won’t be on Wall Street. They’ll be the patients this medicine was supposed […]